Related Experiment Video
Updated: Jul 12, 2025
08:01
Semi-Minimal Invasive Method to Induce Myocardial Infarction in Rats and the Assessment of Cardiac Function by an Isolated Working Heart System
Published on: June 11, 2020
8.2K
α2C-Adrenergic Receptor Blockade Inhibits Langendorff-Isolated Rat Heart Work
T L Zefirov1, L I Khisamieva2, I I Khabibrakhmanov2
1Department of Human Health Protection, Kazan (Volga region) Federal University, Kazan, Republic of Tatarstan, Russia. zefirovtl@mail.ru.
Bulletin of Experimental Biology and Medicine
|October 21, 2023
Summary
The alpha2C-adrenergic receptor antagonist JP-1302 reduced heart rate, contraction force, and coronary flow in isolated rat hearts. Its effects were most potent at 10^-7 M, indicating receptor involvement in cardiac regulation.
Area of Science:
- Pharmacology
- Cardiovascular Physiology
- Adrenergic Receptor Research
Background:
- Alpha2C-adrenergic receptors (α2CARs) are implicated in various physiological processes.
- Their specific role in regulating cardiac function, including contractility and coronary blood flow, requires further elucidation.
Purpose of the Study:
- To investigate the effects of the selective α2CAR antagonist JP-1302 on cardiac function in an isolated rat heart model.
- To determine the concentration-dependent effects of JP-1302 on inotropy, chronotropy, and coronary flow.
Main Methods:
- Utilized the Langendorff-isolated rat heart preparation.
- Administered varying concentrations of JP-1302 (10^-9 M to 10^-6 M) to assess its impact on cardiac parameters.
- Measured left-ventricular developed force, heart rate (HR), and coronary flow.
Main Results:
- JP-1302 consistently decreased left-ventricular myocardium force, HR, and coronary flow across all tested concentrations.
- The most significant negative inotropic, chronotropic, and vascular effects were observed at 10^-7 M JP-1302.
- Lower concentrations (10^-8 M and 10^-9 M) exhibited less pronounced inhibitory effects.
Conclusions:
- Selective α2CAR antagonism with JP-1302 negatively impacts cardiac contractility, heart rate, and coronary perfusion in isolated rat hearts.
- These findings highlight the involvement of α2C-adrenergic receptors in the regulation of adult rat heart activity.
Related Concept Videos
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
496
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
496
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
870
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
870
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
892
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
892
01:31Adrenergic Receptors: ɑ Subtype
1.5K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
752
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
752